Fidia Farmaceutici, SpA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fidia Farmaceutici, SpA
In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.
Pear Therapeutics is restructuring itself to lower costs following repeated disappointing performances.
The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
- Other Names / Subsidiaries
- Fidia Pharma Group
- OftaH.T. e Neoox
- Soluciones Bioregenerativas SL
- Sooft Italia
- Fidia Pharma Austria GmbH